When, 25 years ago, a team of psychiatrists at Yale University tested the intravenous anesthetic ketamine on patients with depression, they did not realize they were on the verge of discovering ketamine’spotential in treating treatment-resistant depression—the researchers called it “the greatest discovery in depression research in the last 50 years.”
What are the key findings?
In fact, the impact of the discovery of this psychedelic’s effects is based on three key findings that have changed the way we understand and treat the disease:
-
Quick and effective action
Unlike traditional antidepressants, which can take weeks to produce results, ketamine improves depressive symptoms within a few hours. This speed represents a radical change in the treatment of severe episodes.
-
A new mechanism of action
Until then, the prevailing theory attributed the effect of antidepressants to the modulation of neurotransmitters such as serotonin, norepinephrine, and dopamine—the so-called monoaminergic hypothesis. Ketamine, however, acts differently, interfering with glutamatergic signaling and inhibiting N-methyl-D-aspartate (NMDA) receptors. Thus, this alternative pathway has opened up new prospects for drug development.
-
Efficacy in treatment-resistant depression (TRD)
Ketamine showed benefits even in patients who did not respond to conventional antidepressants - a group that accounts for around 25% of all cases of depression.
Treatment-Resistant Depression – What Are the Effects of Psychedelic-Assisted Therapy?
The discovery has expanded treatment options. Furthermore, it has challenged and revitalized the theoretical foundations of psychiatry. Today , experts view the use of this psychedelic as one of the most promising strategies for addressing one of the most significant mental health issues of our time.
See our psychedelic-assisted psychotherapy programs here.
